WEP CLINICAL HAS PARTNERED WITH TAIMED BIOLOGICS TO LAUNCH A TROGARZO NAMED PATIENT PROGRAM

 WEP CLINICAL HAS PARTNERED WITH TAIMED BIOLOGICS
TO LAUNCH A TROGARZO NAMED PATIENT PROGRAM

1.Date of occurrence of the event:2023/02/03
2.Company name:TaiMed Biologics Inc.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):Head Office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
 WEP Clinical LTD (WEP), a specialist services company that works with
 pharmaceutical companies to help patients and physicians gain access to
 medicines when no other treatment options are available, has partnered with
 TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO, an
 IV treatment administered every two weeks for patients with muti-drug
 resistant HIV disease.
 The NPP is designed to ensure that physicians in Europe and other regions
 around the world, where TROGARZO is not commercially available, can request
 TROGARZO on behalf of individual patients who have trouble achieving viral
 suppression using standard HIV regimens.
6.Countermeasures:None
7.Any other matters that need to be specified(the information
 disclosure also meets the requirements of Article 7, subparagraph 9
 of the Securities and Exchange Act Enforcement Rules, which brings
 forth a significant impact on shareholders rights or the price of
 the securities on public companies.):
 The company terminated the Trogarzo exclusive marketing right in Europe with
 Theratechnologies  on November 1, 2022. TaiMed and WEP Clinical officially
 signed the service contract for the Post-Approval Named Patient Program
 (NPP) on December 8, 2022 to continue supplying Trogarzo for the need of
 MDR patients in Europe and extend to global regions outside of the United
 States and Canada.